We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.40 | 1.1% | 128.20 | 116,392 | 12:48:45 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 127.60 | 128.80 | 128.80 | 128.00 | 128.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -15.26 | 854.75M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:15:10 | O | 7,807 | 128.102 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/12/2023 | 09:37 | ALNC |  IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data |
| 04/12/2023 | 07:00 | UKREG | Syncona Limited Transaction in Own Shares |
| 01/12/2023 | 14:00 | UKREG | Syncona Limited Total Voting Rights |
| 01/12/2023 | 07:00 | UKREG | Syncona Limited Transaction in Own Shares |
| 30/11/2023 | 07:00 | UKREG | Syncona Limited Transaction in Own Shares |
| 29/11/2023 | 07:00 | UKREG | Syncona Limited Transaction in Own Shares |
| 28/11/2023 | 07:00 | UKREG | Syncona Limited Transaction in Own Shares |
| 27/11/2023 | 19:03 | ALNC | TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one |
| 27/11/2023 | 12:05 | UKREG | Syncona Limited Autolus submits key regulatory filing for obe-cel |
| 27/11/2023 | 07:00 | UKREG | Syncona Limited Transaction in Own Shares |
Syncona (SYNC) Share Charts1 Year Syncona Chart |
|
1 Month Syncona Chart |
Intraday Syncona Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/11/2023 | 11:52 | Wellcome to Syncona | 674 |
| 02/5/2020 | 22:59 | Synchronica - Major management change heralds new strategy | 2 |
| 28/1/2017 | 02:52 | Welcome to Syncona | 2 |
| 20/12/2016 | 15:28 | Synchronica - Mobile Technology - 2012 | 4,755 |
| 08/3/2012 | 00:18 | Synchronica SYNC - Mobile Phone Technology - 2011 | 3,347 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:15:10 | 128.10 | 7,807 | 10,000.92 | O |
| 13:40:08 | 127.75 | 23,125 | 29,542.19 | O |
| 12:48:45 | 128.20 | 1 | 1.28 | AT |
| 12:33:40 | 128.20 | 2 | 2.56 | AT |
| 12:03:40 | 128.80 | 233 | 300.10 | AT |
| Top Posts |
|---|
Posted at 04/12/2023 08:20 by Syncona Daily Update Syncona Limited is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 126.80p.Syncona currently has 666,733,588 shares in issue. The market capitalisation of Syncona is £854,752,460. Syncona has a price to earnings ratio (PE ratio) of -15.26. This morning SYNC shares opened at 128p |
Posted at 29/9/2023 09:10 by the shuffle man Share buy back seems to have stopped the drop for now. |
Posted at 21/9/2023 11:09 by salpara111 I made a small amount of money out of Sync several years ago.Just having another look again given the bombed out share price All of these sort of businesses have been hard hit by the rise in interest rates producing a double whammy of increased funding costs for portfolio companies and less opportunity to get an ipo away. Having said that a point is reached when sentiment is too negative and I think we are nearing that point, having said that, as previous posters have said, the business in now under serious pressure to produce some positive news flow which goes beyond just "we have made good progress with clinical trials" |
Posted at 18/9/2023 08:53 by spectoacc EPIC currently describes the share price :( |
Posted at 11/9/2023 14:07 by tiger blue Yes, very disappointing. At least they got £326m upfront, so the original decision to sell was a good call. The £54.5m write-off of deferred consideration is equivalent to 8.1p per share, so net asset value is now 176.5p based on the latest quarterly update, of which over 51% is in cash. Discount to asset value is now 32%, so still looking very cheap but this is poor for sentiment and to be honest they need some good news to emerge from their drug portfolio to change that. |
Posted at 20/11/2022 21:43 by tiger blue I agree that it was an ambitious statement, but not one they had to make and at this stage unlikely to move the dial much on the share price. They are however serious people who know their sector well, with excellent contacts to enable early access to good science, and it was intriguing that they made it at all. I think they have learned a lot since launch, but still delivered a portfolio IRR of 26% to date, and stepping up the number of company launches with additional recruitment should give a boost. Despite some excellent exits NASDAQ has not been a happy place for their quoted companies, hence what reads as a shift to holding privately to exit with 'like minded' investors. That's not necessarily a bad thing, as Gyroscope had the float badly handled and pulled, but despite that soon after got a nice bid from Novartis. That was their second retinal area sale and they are back in with another new retinal venture. At the end of the day I am there on the basis that anywhere below nav they look on the cheap side, and if they get somewhere close to their target I will be well rewarded. Incidentally, if my use of the compound calculator is correct, it would take a 15% compound return to get to £5 billion over the 10 years. Yes, they have the drag of the capital pool to contend with, but given the portfolio IRR they have achieved to date it's not out of the question. |
Posted at 20/11/2022 20:59 by rambutan2 So was I, so I watched the webcast and have to say that no real guidance was given beyond that the sector itself has tremendous opportunities, and that SYNC is upping its game a tad by taking on more staff. I was hoping that in Q&A at the end one of the analysts would ask the (obvious) question, but none did. They are not upping the amount they invest pa, at least for the time being, and they are intent on keeping a big cash balance - which is sensible but a big drag on returns. Of course, it could be that they are supremely confident one of their current port cos is going to go to the moon, and the beauty of bio investing is that success can bring huge value add. Hmmm... |
Posted at 17/11/2022 10:19 by tiger blue Just listened in on the results presentation, very ambitious targets to grow nav to £5bn over next 10 years from current £1.2bn. Biotech has been and remains a horrible sector for momentum at the moment, but as a tuckaway these look cheap and sentiment alone has been a big driver of the share price. This touched 300p when assets were 215-220p, assets now 203p and shares 175p - with that discount and their ability to incubate companies from interesting science to product development/sale I have added another 25k today. |
Posted at 16/6/2022 15:06 by rambutan2 Finals out, all in all, quite good:The second half of CY2021 was marked by significant volatility across equity markets globally. This uncertainty has carried on into 2022, compounded by concerns around inflation, interest rates and Russia's invasion of Ukraine and the ongoing humanitarian crisis. This has impacted investor sentiment towards risk assets. We have seen a macro rotation away from growth stocks, impacting both valuations and financings of biotech companies, especially smaller, earlier stage companies. As market volatility has increased, the Syncona team continues to carefully review the requirements of each of our portfolio companies and our capital pool to ensure that our Company is well positioned to navigate continuing challenging markets. Our balance sheet provides us with a strategic advantage, and the team's expertise and rigorous approach to risk management means we continue to take a disciplined approach to capital allocation across a well-funded portfolio and exciting pipeline. Syncona ended the year with net assets of GBP1,309.8 million or 194.4p per share, a 0.3 per cent return in the year (31 March 2021: net assets of GBP1,300.3 million, NAV per share of 193.9p, 4.4 per cent return), despite the wider market backdrop for life science companies, which saw the NASDAQ Biotechnology Index decline 12 per cent during the period. The significant NAV uplift achieved through the sale of Gyroscope to Novartis and multiple successful private financings offset the decline in share prices of our three listed companies, Autolus, Freeline and Achilles. We recognise that the performance of these listed companies has been disappointing for our shareholders. Our team have worked closely with portfolio company management teams to support them as they continue to execute their development plans. Similarly, the challenging market conditions have also impacted Syncona's share price performance in the financial year, which has been disappointing. Whilst the market environment for early stage biotech companies continues to be challenging, our listed companies are funded to deliver clinical data which represent key milestones for their businesses, and we believe Syncona is well positioned to deliver growth over the long term. |
Posted at 28/4/2022 19:24 by rambutan2 And to balance things out:Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that it has committed GBP15 million in an oversubscribed GBP75.5 million Series B financing in OMass Therapeutics ("OMass"), a biotechnology company that identifies medicines against highly validated target ecosystems. Syncona was a co-investor in this financing round, which was led by new investors GV, Northpond and Sanofi Ventures. Existing investors Oxford Science Enterprises and Oxford University also joined the round. OMass, an Oxford University spin out, is developing small molecule drugs to treat rare diseases and immunological conditions. The company has a unique approach to the way it finds new medicines. It uses its proprietary drug discovery platform, OdyssION(TM), to more accurately interrogate the target and how it interacts with its native ecosystem. These observations provide potentially critical information that can increase the chances of finding highly effective small molecule medicines that will be successful in clinical trials. This latest financing brings the total amount that OMass has raised to GBP119 million. These proceeds will be used to advance OMass' small molecule portfolio towards clinical trials. This includes progressing the development of small molecule drugs to treat Congenital Adrenal Hyperplasia, Inflammatory Bowel Disease and other inflammatory and rare diseases. Following the Series B financing, Syncona has revalued its existing investment which has resulted in a 32% uplift in the value of its stake in OMass. Including the drawdown of the first tranche of Syncona's Series B investment of GBP15 million, Syncona's holding value of OMass is now GBP44 million. On drawdown of the full Series B financing, Syncona's ownership stake in OMass will be 31 per cent. Edward Hodgkin, Chair of OMass and Partner at Syncona said: "We are pleased with this financing round which will support OMass as it looks to progress its pipeline of small molecule drugs. The strength of this global group of top tier life science investors reflects confidence in the company's technology and supports our ambition to build a sustainable therapeutics business that has the potential to develop novel drugs in areas of high unmet medical need . This financing represents a further validation of the ability of Syncona's portfolio companies to attract high quality syndicates, to fund them over the long-term." |
Posted at 14/11/2021 16:12 by sev22 The Syncona Investment Trust, a member of Interactive Investor’s ACE 40 rated list of ethical investments, has reported its latest half-yearly results (11th November 2021):Syncona Ord (SYNC) investment trust, which invests in life science companies, reported a decline in net asset value of 11.4% for the first six months of its financial year – from the end of March to the end of September. Over this period, the trust reported that its net assets sat at £1.15 billion, down from £1.3 billion at the end of March 2021. Figures from FE Analytics show that over this period its share price total return was a loss of 33.6%, suffering from its high premium notably declining. The decline, the report notes, was driven predominantly by the decline in the share price of two of the trust’s listed holdings, Freeline Therapeutics Holdings ADR FRLN and Achilles Therapeutics ADR ACHL. Freeline’s poor performance is put down to “operational challenges” owing to the Covid-19 pandemic. Syncona says these concerns have now been addressed. Achilles’ share price decline was driven by “market sentiment towards cell and gene therapies”. Syncona says that it believes the business is performing well and in line with expectations. The trust’s strategy is to establish, build and fund companies to turn exceptional science into a dynamic portfolio of global leaders in life sciences. The aim is for the companies to deliver their product to market. The trust has a long-term target of owning between 15 and 20 companies. It currently has 10. Martin Murphy, chief executive of Syncona Investment Management Limited, said: “While we are disappointed by the decline in NAV during the period, we are continuing to build a diverse portfolio across the development cycle and therapeutic areas and remain confident in our companies' potential. The substantial capital that a number of our companies have accessed so far this year validate the significant opportunity ahead for them.” The trust also said that it planned to deploy another £100 million to £175 million into both existing companies and new opportunities this year. Murphy said: “With clinical data the key driver of value and risk for Syncona, we believe our companies are well positioned and on track to further validate our model and strategy in the next 12 months with the potential for a rich seam of data.” The trust is a member of Interactive Investor’s ACE 40 rated list of ethical investments. It was placed under formal review in the summer due to the volatility of its share price, but it kept its place on the list. Dzmitry Lipski, head of funds research at Interactive Investor, notes: “We remain positive on the trust outlook and see it as a strong choice for adventurous investors prepared to tolerate high volatility in the short term, but potentially reap rewards over the longer term. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
